• Insider Monkey

    ChatGPT Stock Portfolio: Top 10 Picks

    In this article, we will take a look at ChatGPT stock portfolio. To see more such companies, go directly to ChatGPT Stock Portfolio: Top 5 Picks. If there’s one thing that can be learned from literally hundreds of ChatGPT-related posts out there claiming that the AI chatbot has successfully beaten the market, it’s that ChatGPT’s […]

  • TheStreet.com

    Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

    Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Johnson & Johnson recently was downgraded to Hold with a C+ rating by TheStreet's Quant Ratings.

  • Motley Fool

    Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years

    Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years. With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS). As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.

  • Simply Wall St.

    Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)

    Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$373 Current share price of...

  • Motley Fool

    Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It Could Jump a Lot More

    Wall Street thinks this stock will rise 12% over the next 12 months. Let's first address why some on Wall Street don't have greater expectations for Vertex. One of the biggest factors is the biotech stock's previous success.

  • Motley Fool

    Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever

    The good news is that if you've got the money and the time, it's not all that hard to find great investment options. If the company hits the high end of that range and its share price grows to reflect that internal growth, an initial investment of $10,000 would increase in value to over $163,000 in two decades. The company's infrastructure assets include natural gas pipelines, electricity transmission lines, smart meters, rail operations, toll roads, telecom towers, data centers, and semiconductor manufacturing foundries.

  • Motley Fool

    Buy the Dip On These Warren Buffett Stocks

    If you're like Warren Buffett, you favor solid companies that perform over the long term -- and, at the same time, reward investors with passive income. Buffett has made his fortune -- and the fortune of others as Berkshire Hathaway chairman -- by sticking to that idea. Well, an opportunity is here for two Buffett favorites.

  • Motley Fool

    Investing $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income

    If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long game. Building up a passive income stream is often a lot more manageable when you can do it piece by piece rather than paying out a large lump sum. Dollar-cost averaging (DCA) refers to buying a few shares of a stock here and there over a period of time so that you don't need a lump sum to reach your target position size.

  • Motley Fool

    3 No-Brainer Stocks to Buy for Under $100 Right Now

    Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics):  Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.

  • Motley Fool

    The Best Stocks to Invest $20,000 in Right Now

    Warren Buffett thinks that near-term economic and market forecasts are "worse than useless." My hunch is that the U.S. economy is headed for a mild recession. Like most investors who aren't billionaires with the surname Buffett, I don't like to see the stocks I buy go down.

  • Bloomberg

    Tylenol-Maker Kenvue Poised to Get Wall Street Ratings After IPO

    (Bloomberg) -- Kenvue Inc., the consumer health business that Johnson & Johnson spun off this month, will be eligible for ratings from a slew of major Wall Street banks next week, offering a chance to see how analysts are assessing initial public offerings amid the latest equities volatility and recession worries. Most Read from BloombergBiden, McCarthy Forge Debt Deal in Bid to Avert US DefaultWorld’s Richest Man Throws In Towel on Beverly Hills HotelKey Takeaways From Deal Biden, GOP Sealed to

  • Investor's Business Daily

    Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

    An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

  • Investor's Business Daily

    Arcus, Iteos Soar On Roche's 'Meaningful' Results In A New Cancer Drug Class

    Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.

  • PR Newswire


    Amgen (NASDAQ: AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

  • Insider Monkey

    Louis Navellier’s 2023 Portfolio: 15 Growth Stocks to Watch

    In this article, we discuss 15 growth stocks to watch in Louis Navellier’s 2023 portfolio. If you want to see more stocks in this selection, check out Louis Navellier’s 2023 Portfolio: 5 Growth Stocks to Watch. According to a report featured on Markets Insider in October 2022, Louis Navellier of Navellier & Associates said that the […]

  • The Wall Street Journal

    Next Covid Boosters to Target New Strain

    Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.

  • Zacks

    Novo Nordisk (NVO) Growth Hormone Drug Gets Positive CHMP Opinion

    Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.

  • Zacks

    Bristol Myers (BMY) Thrombosis Drug Gets Fast Track Designation

    Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.

  • Barrons.com

    Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.

    Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present at the annual meeting.

  • Zacks

    Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

    Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Zacks

    Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?

    BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Insider Monkey

    12 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain

    In this article, we discuss 12 best growth stocks to buy and hold in 2023 according to billionaire Rajiv Jain. If you want to see more stocks in this selection, check out 5 Best Growth Stocks to Buy and Hold in 2023 According to Billionaire Rajiv Jain. Bloomberg reported on May 23 that Rajiv Jain, […]

  • Zacks

    Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults

    Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.

  • Zacks

    Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

    A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

  • Zacks

    Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use

    Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.